<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18290">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875510</url>
  </required_header>
  <id_info>
    <org_study_id>B.10.4.Ä°SM.4.06.68.49/144</org_study_id>
    <nct_id>NCT01875510</nct_id>
  </id_info>
  <brief_title>The Influence of Fish-oil Lipid Emulsions on Neonatal Morbidities</brief_title>
  <official_title>The Effect of Fish-oil Lipid Emulsions on Neonatal Cholestasis and Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Sami Ulus Children's Hospital</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docosahexaenoic acid (DHA) has been shown to be particularly important for fetal and
      neonatal development. Infants born prematurely are at special risk for DHA insufficiency.
      The source of DHA after birth for preterm babies who are not fed full enterally, are mostly
      fat emulsions as the component of total parenteral nutrition solutions which usually do not
      contain DHA. The aim of this study is to investigate if the fish oil emulsion-administered
      from the first day of life and during parenteral nutrition-prevents infants from cholestasis
      and retinopathy of prematurity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Stage of retinopathy of prematurity (I-V)</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <condition>Neonatal Cholestasis</condition>
  <arm_group>
    <arm_group_label>Fish-oil emulsions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>soybean-oil emulsion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fish -oil emulsions</intervention_name>
    <description>none</description>
    <arm_group_label>Fish-oil emulsions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soybean-oil emulsion</intervention_name>
    <arm_group_label>soybean-oil emulsion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants below 32 gestational age and requiring parenteral nutrition

        Exclusion Criteria:

          -  Infants with congenital anomalies, infants above 32 gestational age
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Serdar Beken</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Sami Ulus Childrens Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serdar Beken, M.D</last_name>
      <phone>00903123056449</phone>
      <email>serbeken@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Serdar Beken, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Pawlik D, Lauterbach R, Turyk E. Fish-oil fat emulsion supplementation may reduce the risk of severe retinopathy in VLBW infants. Pediatrics. 2011 Feb;127(2):223-8. doi: 10.1542/peds.2010-2427. Epub 2011 Jan 3.</citation>
    <PMID>21199856</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 7, 2013</lastchanged_date>
  <firstreceived_date>May 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Sami Ulus Children's Hospital</investigator_affiliation>
    <investigator_full_name>Serdar Beken</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
